September 16, 2026

Hot drink habits and esophageal cancer

Researchers assessed preferred hot drink temperature and consumption frequency across 2 large UK cohorts.

MDSpire News

September 15, 2026

Photodynamic therapy gains FDA approval for superficial BCC

Phase 3 trial data showed greater clinical and histological clearance than with placebo photodynamic therapy.

MDSpire News

September 14, 2026

FDA approves FET-PET agent for glioma

The radioactive diagnostic drug is indicated in patients aged 1 month or older and is used in conjunction with other diagnostic evaluations.

MDSpire News

September 09, 2026

FDA expands sevabertinib approval in NSCLC

SOHO-01 data showed a 75% confirmed objective response rate among 69 patients without previous systemic therapy.

MDSpire News

September 08, 2026

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.

MDSpire News

September 08, 2026

Triple-positive profile may flag adverse prostate cancer pathology

A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.

MDSpire News

September 03, 2026

AI cuts lesion measurement time by 34%

Automated lesion measurements increased agreement on treatment response, although expert-generated proposals were accepted more often and required fewer adjustments.

MDSpire News

September 01, 2026

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

MDSpire News

August 28, 2026

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

August 25, 2026

FDA expands gastroesophageal cancer options

Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.

MDSpire News